Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Committee for Scientific Affairs TJAfTS, Masuda M, Okumura M, et al. Thoracic and cardiovascular surgery in Japan during 2014: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016;64(11):665–697. doi:10.1007/s11748-016-0695-327590348
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Kim ES, Zhang J, Smith MM, Rangwala RA, O′Brien MER. KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). J Clin Oncol. 2015;33(15_suppl):TPS8103–TPS8103.
   Google Scholar
• Sawabata N, Miyaoka E, Asamura H, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6(7):1229–1235.21610521
   PubMed Web of Science ®Google Scholar
• Gwozdz P, Pasieka-Lis M, Kolodziej K, et al. Prognosis of patients with stages I and II non-small cell lung cancer with nodal micrometastases. Ann Thorac Surg. 2018;105(5):1551–1557.29305849
   PubMed Web of Science ®Google Scholar
• Sowa T, Menju T, Sonobe M, et al. Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma. Cancer Med. 2015;4(12):1853–1862.26471868
   PubMed Web of Science ®Google Scholar
• Sabe H. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor beta signalling. J Biochem. 2011;149(6):633–639.21478191
   PubMed Web of Science ®Google Scholar
• Menju T, Sowa T, Sonobe M, et al. Clinicopathologic significance of epithelio-mesenchymal transition in human lung adenocarcinomas: an integrative analysis, inclusive of genetic alterations, on 256 surgically resected cases. Cancer Treat Res Commun. 2017;12:62–68.
   Google Scholar
• Wang SP, Wang WL, Chang YL, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of slug. Nat Cell Biol. 2009;11(6):694–704.19448627
   PubMed Web of Science ®Google Scholar
• Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32(27):3286–3295. doi:10.1038/onc.2012.33422847613
   PubMed Web of Science ®Google Scholar
• Alexandrova EM, Yallowitz AR, Li D, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015;523(7560):352–356. doi:10.1038/nature1443026009011
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148(1–2):244–258. doi:10.1016/j.cell.2011.12.01722265415
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Oikawa T, Hashimoto S, et al. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. J Cell Biol. 2016;213(1):81–95. doi:10.1083/jcb.20151000227044891
   PubMed Web of Science ®Google Scholar
• Alizadeh J, Zeki AA, Mirzaei N, et al. Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep. 2017;7:44841. doi:10.1038/srep4484128344327
   PubMed Web of Science ®Google Scholar
• Shi Y, Felley-Bosco E, Marti TM, Stahel RA, Aboussekhra A. Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy. PLoS One. 2012;7(9):e45354. doi:10.1371/journal.pone.004535423028957
   PubMed Web of Science ®Google Scholar
• Lin JJ, Ezer N, Sigel K, Mhango G, Wisnivesky JP. The effect of statins on survival in patients with stage IV lung cancer. Lung Cancer. 2016;99:137–142. doi:10.1016/j.lungcan.2016.07.00627565929
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Mc Menamin U, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015;24(5):833–841. doi:10.1158/1055-9965.EPI-15-005225934831
   PubMed Web of Science ®Google Scholar
• Hung MS, Chen IC, Lee CP, et al. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One. 2017;12(2):e0171137. doi:10.1371/journal.pone.017113728158206
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee KH, Lee GK, et al. Randomized phase II study of afatinib plus simvastatin versus afatinib alone in previously treated patients with advanced non-adenocarcinomatous non-small cell lung cancer. Cancer Res Treat. 2017. doi:10.4143/crt.2016.546
   Web of Science ®Google Scholar
• Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.739128240967
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.1016968952
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-194720068163
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Menju T, Nishikawa S, et al. The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer. Cancer Med. 2018;7(2):408–419. doi:10.1002/cam4.128229318780
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallionimeni A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844.9662379
   PubMed Web of Science ®Google Scholar
• Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–2561. doi:10.1056/NEJMoa07377018094376
   PubMed Web of Science ®Google Scholar
• Molina-Vila MA, Bertran-Alamillo J, Gasco A, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2014;20(17):4647–4659. doi:10.1158/1078-0432.CCR-13-239124696321
   PubMed Web of Science ®Google Scholar
• Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14(6):680–686. doi:10.1097/01.EDE.0000081989.82616.7d14569183
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45. doi:10.1161/01.cir.0000437738.63853.7a24222016
   PubMed Web of Science ®Google Scholar
• Courtin A, Smyth T, Hearn K, et al. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. Br J Cancer. 2016;115(9):1069–1077. doi:10.1038/bjc.2016.29427673365
   PubMed Web of Science ®Google Scholar
• Yang Z, Su Z, DeWitt JP, et al. Fluvastatin prevents lung adenocarcinoma bone metastasis by triggering autophagy. EBioMedicine. 2017;19:49–59.28454732
   PubMed Web of Science ®Google Scholar
• Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol. 2011;6(11):1784–1792.21964532
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8.23263379
   PubMed Web of Science ®Google Scholar
• Solomon H, Buganim Y, Kogan-Sakin I, et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 2012;125(Pt 13):3144–3152.22427690
   PubMed Web of Science ®Google Scholar
• Salari A, Thomay K, Lentes J, et al. Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model. Oncotarget. 2018;9(52):29869–29876.30042819
   PubMedGoogle Scholar
• van Oijen MGCT, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 2000;6(6):2138.10873062
   PubMed Web of Science ®Google Scholar
• Turrell FK, Kerr EM, Gao M, et al. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity. Genes Dev. 2017;31(13):1339–1353.28790158
   PubMed Web of Science ®Google Scholar
• Parrales A, Ranjan A, Iyer SV, et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016;18(11):1233–1243.27775703
   PubMed Web of Science ®Google Scholar
• Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-Bis(2-chloroethyl)-N-nitrosourea and β-interferon on human glioma cells. Cancer Res. 1992;52(16):4348.1643632
   PubMed Web of Science ®Google Scholar
• Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508.11960327
   PubMed Web of Science ®Google Scholar
• Kim S. New and emerging factors in tumorigenesis: an overview. Cancer Manag Res. 2015;7:225–239.26251629
   PubMed Web of Science ®Google Scholar
• Park YH, Jung HH, Ahn JS, Im YH. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun. 2013;439(2):275–279.23973711
   PubMed Web of Science ®Google Scholar
• Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7(3):2532–2544.26565813
   PubMedGoogle Scholar
• Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69(8):3256–3261.19351834
   PubMed Web of Science ®Google Scholar
• Robin NC, Agoston Z, Biechele TL, James RG, Berndt JD, Moon RT. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Stem Cell Rep. 2014;2(1):9–17.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743–751.12783420
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Sun J-S, Tsuang Y-H, Chen M-H, Weng P-W, Lin F-H. Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res. 2010;30(3):191–199.20417880
   PubMed Web of Science ®Google Scholar
• Lee DK, Park EJ, Kim EK, et al. Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Cell Physiol Biochem. 2012;30(3):499–511.22814256
   PubMedGoogle Scholar
• Aisner DL, Sholl LM, Berry LD, et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018;24(5):1038–1047.29217530
   PubMed Web of Science ®Google Scholar
• Deben C, Deschoolmeester V, Lardon F, Rolfo C, Pauwels P. TP53 and MDM2 genetic alterations in non-small cell lung cancer: evaluating their prognostic and predictive value. Crit Rev Oncol Hematol. 2016;99:63–73.26689115
   PubMed Web of Science ®Google Scholar
• Bockorny B, Dasanu CA. HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence? Ann Hematol. 2015;94(1):1–12.25416152
   PubMed Web of Science ®Google Scholar
• Kodach LL, Jacobs RJ, Voorneveld PW, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell ‘stemness‘ via the bone morphogenetic protein pathway. Gut. 2011;60(11):1544–1553.21551187
   PubMed Web of Science ®Google Scholar
• Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):695–712.27146293
   PubMed Web of Science ®Google Scholar